Johnson & Johnson reported second-quarter results on July 16. Sales of pharmaceuticals have been muted due to a loss of market exclusivity for Stelara. A strong medical technology segment and an ...
For decades, Johnson & Johnson (NYSE: JNJ) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received. When the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results